Department of Urology, West China Xiamen Hospital, Sichuan University, Xiamen, China.
Department of Urology, West China Hospital, Sichuan University, Chengdu, China.
BMC Urol. 2024 Sep 5;24(1):193. doi: 10.1186/s12894-024-01582-w.
Benign prostatic hyperplasia (BPH) is a prevalent urological disease in elderly males. However, few studies have estimated the temporal and spatial distributions of the BPH burden in male adults aged 60 years and over at the global, national, and regional scales.
Leveraging the Global Burden of Disease, Injuries, and Risk Factors Study, we estimated the global epidemiological trends in the prevalence, incidence, and disability-adjusted life-years (DALYs) of BPH in 204 countries and 21 regions and 5 sociodemographic index (SDI) regions in males aged 60 years and over between 1990 and 2019. The average annual percentage changes (AAPCs) in age-specific rates were estimated to quantify overall trends. We estimated the contribution of population aging and epidemiological alterations in disease burden via composition analysis.
Over the past three decades, the global prevalent cases, incident cases and DALYs of BPH have increased, ranging from 118.78 to 121.22%. The global number of prevalent BPH cases reached 79 million in people aged 60 years and older in 2019. The prevalence, incidence, and DALYs rates gradually increased, with AAPCs of 0.02, 0.02, and 0.01, respectively. Low-middle, middle, and low SDI regions experienced rapid increases in the number of prevalent cases of BPH. In 2019, China, India, and United States of America bore the largest burden of prevalent cases among people aged 60 years and over. The three regions with the highest prevalence rates of BPH were Eastern Europe, Central Latin America, and Andean Latin America. The increased prevalence was attributed to population growth (94.93%), epidemiological changes (3.45%), and aging (1.62%), globally.
BPH is a global health issue that imposes substantial economic burdens on most countries, particularly males aged 60 years and over. Effective health decisions are imperative for BPH prevention and treatment.
良性前列腺增生（BPH）是老年男性中常见的泌尿系统疾病。然而，很少有研究在全球、国家和地区范围内评估 60 岁及以上男性成年人的 BPH 负担的时空分布。
利用全球疾病、伤害和危险因素研究（GBD），我们估计了 1990 年至 2019 年期间，204 个国家和 21 个地区以及 5 个社会人口指数（SDI）地区 60 岁及以上男性中 BPH 的流行率、发病率和伤残调整生命年（DALY）的全球流行病学趋势。我们估计了年龄特异性发病率的年均百分比变化（AAPC），以量化总体趋势。我们通过构成分析来估计人口老龄化和疾病负担中疾病流行病学变化的贡献。
在过去的三十年中，全球 BPH 的现患病例、发病病例和 DALY 呈上升趋势，范围在 118.78 至 121.22%之间。2019 年，60 岁及以上人群中 BPH 的现患病例数达到 7900 万。BPH 的流行率、发病率和 DALY 率逐渐上升，AAPC 分别为 0.02、0.02 和 0.01。中低等、中等和低等 SDI 地区的 BPH 现患病例数增长迅速。2019 年，中国、印度和美国在 60 岁及以上人群中现患病例数最多。BPH 发病率最高的三个地区是东欧、中拉丁美洲和安第斯拉丁美洲。全球范围内，BPH 流行率的增加归因于人口增长（94.93%）、流行病学变化（3.45%）和老龄化（1.62%）。
BPH 是一个全球性的健康问题，给大多数国家带来了巨大的经济负担，特别是 60 岁及以上的男性。有效的健康决策对于 BPH 的预防和治疗至关重要。
